Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer.

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Open Medicine Pub Date : 2025-08-07 eCollection Date: 2025-01-01 DOI:10.1515/med-2024-1071

Wugang Zhu, Wenjing Xu, Degan Liu, Lei Wan, Xiaolan Lu

{"title":"Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer.","authors":"Wugang Zhu, Wenjing Xu, Degan Liu, Lei Wan, Xiaolan Lu","doi":"10.1515/med-2024-1071","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to assess the clinical effectiveness and safety of combining immunotherapy with chemotherapy for non-small cell lung cancer.Methods: A comprehensive search of studies published until January 2024 was conducted. Quality assessment was performed using the NOS scale, and a meta-analysis was carried out with RevMan 5.4.1 software. Heterogeneity was assessed using the Q-test, and combined effects were calculated with fixed or random effects models. Results were visualized using forest plots, and a sensitivity analysis was performed.Results: Out of 1,061 sources, 11 met the inclusion criteria. The meta-analysis indicated that the combination treatment significantly improved 1-year overall survival, objective response rate, and disease control rate compared to chemotherapy alone (P < 0.05), with no significant difference in adverse reactions (P > 0.05). Immune function markers CD4+ and CD4+/CD8+ were higher, and CD8+ was lower in the combined treatment group. Sensitivity analysis confirmed the stability and reliability of the results (OR (95% CI) 3.72 (2.34-5.90), P < 0.00001), although publication bias was indicated by funnel plots.Conclusion: The combination of chemotherapy and immunotherapy exhibits the potential to enhance both survival rates and clinical effectiveness, without the concomitant rise in severe adverse reactions.","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20241071"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355367/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/med-2024-1071","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to assess the clinical effectiveness and safety of combining immunotherapy with chemotherapy for non-small cell lung cancer.

Methods: A comprehensive search of studies published until January 2024 was conducted. Quality assessment was performed using the NOS scale, and a meta-analysis was carried out with RevMan 5.4.1 software. Heterogeneity was assessed using the Q-test, and combined effects were calculated with fixed or random effects models. Results were visualized using forest plots, and a sensitivity analysis was performed.

Results: Out of 1,061 sources, 11 met the inclusion criteria. The meta-analysis indicated that the combination treatment significantly improved 1-year overall survival, objective response rate, and disease control rate compared to chemotherapy alone (P < 0.05), with no significant difference in adverse reactions (P > 0.05). Immune function markers CD4+ and CD4+/CD8+ were higher, and CD8+ was lower in the combined treatment group. Sensitivity analysis confirmed the stability and reliability of the results (OR (95% CI) 3.72 (2.34-5.90), P < 0.00001), although publication bias was indicated by funnel plots.

Conclusion: The combination of chemotherapy and immunotherapy exhibits the potential to enhance both survival rates and clinical effectiveness, without the concomitant rise in severe adverse reactions.

Abstract Image

查看原文本刊更多论文

免疫治疗联合化疗治疗非小细胞肺癌的临床疗效和安全性荟萃分析。

目的：本研究旨在评价免疫联合化疗治疗非小细胞肺癌的临床有效性和安全性。方法：对2024年1月前发表的研究进行全面检索。采用NOS量表进行质量评价，采用RevMan 5.4.1软件进行meta分析。异质性采用q检验评估，联合效应采用固定或随机效应模型计算。使用森林图将结果可视化，并进行敏感性分析。结果：1061份文献中，11份符合纳入标准。荟萃分析显示，联合治疗与单独化疗相比，1年总生存率、客观有效率、疾病控制率均显著提高（P < 0.05），不良反应差异无统计学意义（P < 0.05）。联合治疗组免疫功能指标CD4+、CD4+/CD8+升高，CD8+降低。敏感性分析证实了结果的稳定性和可靠性(OR (95% CI) 3.72 (2.34-5.90), P < 0.00001)，尽管漏斗图显示发表偏倚。结论：化疗联合免疫治疗可提高患者的生存率和临床疗效，且未出现严重不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Medicine Medicine-General Medicine

CiteScore

3.00

自引率

0.00%

发文量

153

审稿时长

20 weeks

期刊介绍： Open Medicine is an open access journal that provides users with free, instant, and continued access to all content worldwide. The primary goal of the journal has always been a focus on maintaining the high quality of its published content. Its mission is to facilitate the exchange of ideas between medical science researchers from different countries. Papers connected to all fields of medicine and public health are welcomed. Open Medicine accepts submissions of research articles, reviews, case reports, letters to editor and book reviews.